




RealRate

MEDICINAL PRODUCTS 2019

Intellia Therapeutics Inc.
Rank 13 of 50





RealRate

MEDICINAL PRODUCTS 2019

Intellia Therapeutics Inc. Rank 13 of 50



The relative strengths and weaknesses of Intellia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intellia Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 108% points. The greatest weakness of Intellia Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 90%, being 96% points above the market average of -5.9%.

Input Variable	Value in 1000 USD
Assets, Current	324,977
Assets, Non-Current	5,277
General and Administrative Expense	32,189
Goodwill	0
Liabilities, Current	40,572
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-28
Other Expenses	0
Other Liabilities	0
Other Net Income	5,527
Other Revenues	30,434
Property, Plant and Equipment, Net	17,061
Research and Development	89,115

Output Variable	Value in 1000 USD
Liabilities	40,572
Assets	347,315
Expenses	121,304
Revenues	30,434
Stockholders Equity	306,743
Net Income	-85,343
Comprehensive Net Income	-85,357
Economic Capital Ratio	90%